硫酸软骨素和氨基葡萄糖用于治疗颞下颌关节紊乱症的疗效：一项系统评价和荟萃分析。
Efficacy of the use of chondroitin sulphate and glucosamine for the treatment of temporomandibular joint dysfunction: A systematic review and meta-analysis.
作者信息
Ruiz-Romero Víctor, Toledano-Serrabona Jorge, Gay-Escoda Cosme
机构信息
Faculty of Medicine and Health Sciences, Dental School, University of Barcelona, Barcelona, Spain.
Odontological and Maxillofacial Pathology and Therapeutics Group, IDIBELL (Bellvitge Biomedical Research Institute), Barcelona, Spain.
出版信息
Cranio. 2025 Jan;43(1):60-69. doi: 10.1080/08869634.2022.2076796. Epub 2022 May 19.
OBJECTIVE
To evaluate the efficacy of chondroitin sulfate (CS) and glucosamine (GS), the most relevant drugs of "Symptomatic Slow Acting Drug for Osteoarthritis" (SYSADOA), in the functional and symptomatic improvement of temporomandibular dysfunction. Although, controversy exists regarding their benefit.
METHODS
An electronic search was conducted to retrieve randomized controlled clinical trials (RCTs). The risk of bias assessment was evaluated using the Cochrane Collaboration's tool. Data were meta-analyzed with a random effect model whenever possible.
RESULTS
Three RCTs were included. Qualitative results showed a decrease in pain, joint noise, and inflammatory biomarkers in synovial fluid and an improvement in maximum mouth opening without significant adverse effects. Meta-analysis showed a significant increase in maximum mouth opening with the use of CS-GS ( = 0.19). No statistically significant differences were found in pain reduction compared to tramadol.
CONCLUSION
CS-GS is effective and safe in the symptomatic and functional improvement of patients with TMD.
目的
评估硫酸软骨素（CS）和氨基葡萄糖（GS）这两种“骨关节炎症状性慢作用药物”（SYSADOA）中最相关的药物对颞下颌关节紊乱症功能和症状改善的疗效。尽管关于它们的益处存在争议。
方法
进行电子检索以获取随机对照临床试验（RCT）。使用Cochrane协作网的工具评估偏倚风险。尽可能采用随机效应模型对数据进行荟萃分析。
结果
纳入三项RCT。定性结果显示疼痛减轻、关节弹响减少、滑液中炎症生物标志物减少，最大开口度改善，且无明显不良反应。荟萃分析显示使用CS - GS后最大开口度显著增加（= 0.19）。与曲马多相比，在疼痛减轻方面未发现统计学显著差异。
结论
CS - GS对颞下颌关节紊乱症患者的症状和功能改善有效且安全。
Zotero 插件